Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 77 citing articles:

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
Yufei Chen, Yingying Xu, Zhi‐Ming Shao, et al.
Cancer Communications (2022) Vol. 43, Iss. 3, pp. 297-337
Open Access | Times Cited: 67
Future directions for the discovery of natural product-derived immunomodulating drugs: an IUPHAR positional review
Cherry L. Wainwright, Mauro Martins Teixeira, David L. Adelson, et al.
Pharmacological Research (2022) Vol. 177, pp. 106076-106076
Open Access | Times Cited: 53
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers
Wei Sun, Ruochen Liu, Xinyue Gao, et al.
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 32
Antibody-Drug Conjugates in Gynecologic Cancers
Mary Katherine Anastasio, Stephanie Shuey, Brittany A. Davidson
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 1-19
Closed Access | Times Cited: 11
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 8
Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report
Yong Wu, Lingfang Xia, Chunyan Song, et al.
Journal of Ovarian Research (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial
Emiliano Cappello, Paola Nieri
Life (2021) Vol. 11, Iss. 12, pp. 1390-1390
Open Access | Times Cited: 46
Development of Marine-Derived Compounds for Cancer Therapy
Weimin Zuo, Hang Fai Kwok
Marine Drugs (2021) Vol. 19, Iss. 6, pp. 342-342
Open Access | Times Cited: 44
Facts and Hopes in Immunotherapy of Endometrial Cancer
Juan A. Marín‐Jiménez, Sandra García‐Mulero, Xavier Matías‐Guiu, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 22, pp. 4849-4860
Open Access | Times Cited: 34
Antibody-Drug Conjugates in Gynecologic Cancer
Hannah Karpel, Sachia Stonefeld Powell, Bhavana Pothuri
American Society of Clinical Oncology Educational Book (2023), Iss. 43
Open Access | Times Cited: 22
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)
Arianna Dri, Grazia Arpino, Giampaolo Bianchini, et al.
Cancer Treatment Reviews (2023) Vol. 123, pp. 102672-102672
Open Access | Times Cited: 21
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
Giorgio Bogani, Robert L. Coleman, Ignace Vergote, et al.
International Journal of Gynecological Cancer (2023) Vol. 34, Iss. 4, pp. 469-477
Closed Access | Times Cited: 21
Integrating antibody drug conjugates in the management of gynecologic cancers
Anca Chelariu-Raicu, Sven� Mahner, Kathleen N. Moore, et al.
International Journal of Gynecological Cancer (2023) Vol. 33, Iss. 3, pp. 420-429
Closed Access | Times Cited: 20
Therapeutic strategies targeting folate receptor α for ovarian cancer
Jia Mai, Limei Wu, Ling Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
Emerging Targets in Non-Small Cell Lung Cancer
Louisa Liu, Joshua Soler, Karen L. Reckamp, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10046-10046
Open Access | Times Cited: 7
Natural Products Derived from Marine Sponges with Antitumor Potential against Lung Cancer: A Systematic Review
Alba Ortigosa‐Palomo, Francisco Quiñonero, Raúl Ortíz, et al.
Marine Drugs (2024) Vol. 22, Iss. 3, pp. 101-101
Open Access | Times Cited: 6
The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
Xinlin Liu, Junwen Deng, Renshuai Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Top advances of the year: Ovarian cancer
Melissa Lumish, Elise C. Kohn, William P. Tew
Cancer (2023) Vol. 130, Iss. 6, pp. 837-845
Closed Access | Times Cited: 13
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Giovanni Tonon, Flavio Rizzolio, Fabiano Visentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8651-8651
Open Access | Times Cited: 5
Unveiling the Therapeutic Potential of Folate-Dependent One-Carbon Metabolism in Cancer and Neurodegeneration
Ana Filipa Sobral, Andrea Cunha, Vera Silva, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9339-9339
Open Access | Times Cited: 5
Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy
Andrey A. Zamyatnin, Levy C Gregory, Paul A. Townsend, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 11, pp. 963-977
Open Access | Times Cited: 22
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Thomas J. Herzog, Sandro Pignata, Sharad Ghamande, et al.
Gynecologic Oncology (2023) Vol. 170, pp. 300-308
Closed Access | Times Cited: 12
Evaluation of Folate-Functionalized Nanoparticle Drug Delivery Systems—Effectiveness and Concerns
Muhammad Aiman Irfan Ibrahim, Rozana Othman, Chin Fei Chee, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2080-2080
Open Access | Times Cited: 12
Drug Discovery from Natural Sources
David Newman
Current Pharmacology Reports (2023) Vol. 9, Iss. 2, pp. 67-89
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top